全球口咽念珠菌念珠菌症市场：按类型、按治疗、按给药途径、按分销管道、按地区

2023 年，全球口咽念珠菌症市场价值为 4.56 亿美元，预计到 2031 年将达到 6.304 亿美元，2024 年至 2031 年复合年增长率为 4.1%。

图 1. 2024 年口咽念珠菌念珠菌症全球市场占有率(%)（按地区）

口咽念珠菌症（OPC），通常也称为鹅口疮，是由口腔和咽黏膜念珠菌（主要是白色念珠菌）过度生长引起的真菌感染疾病。念珠菌是口腔微生物群的正常组成部分，但在某些条件下，微生物的微妙平衡被破坏，念珠菌过度生长。常见于免疫系统较弱的族群，例如患有人类免疫力缺乏病毒/后天免疫力缺乏症候群（爱滋病毒/爱滋病）的人、接受化疗的人以及服用广谱抗生素的人。它也可能发生在糖尿病患者、服用皮质类固醇的患者和佩戴假牙的患者。这种感染疾病的特征通常是舌头、脸颊内侧、上颚、牙龈、扁桃体和喉咙后部出现白斑。这些病变可能会稍微隆起，在严重的情况下，可能会导致不适和吞嚥困难。念珠菌症是一种由于其在免疫力缺乏人群中的流行而在医学研究和患者照护中受到高度关注的疾病。儘管念珠菌是无害的，并且是大多数人口腔菌群的标准居民，但多种情况都可能导致这种感染，包括免疫力缺乏、长期使用抗生素、糖尿病和某些药物治疗。机会性真菌感染疾病。这种感染疾病的特征性症状是口腔和咽部黏膜表面出现乳白色病变。这些病变有时会令人不舒服，如果广泛传播，可能会干扰适当的营养和吞嚥。 OPC 的治疗通常涉及抗真菌药物，重点是解决可能导致真菌过度生长的潜在疾病。市场分析表明，该疾病的治疗领域受到全球糖尿病和爱滋病毒/爱滋病高盛行率的显着影响，导致对有效抗真菌疗法的需求不断增加。

市场动态：

全球口咽念珠菌症市场是由爱滋病毒/爱滋病盛行率上升以及更容易受到真菌感染疾病的老年人口增加所推动的。此外，日益激进的肿瘤定向治疗，以及频谱抗生素和皮质类固醇治疗的频繁使用，正在加剧鹅口疮的风险。然而，市场可能面临限制因素，例如学名药竞争加剧和替代治疗方案的可用性。

本研究的主要特点

• 本报告对全球口咽念珠菌念珠菌症市场进行了详细分析，并列出了以2023年为基准年的预测期（2024-2031）的市场规模和復合年增长率。
• 它还说明了各个细分市场的潜在商机，并为该市场提供了一系列有吸引力的投资提案。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
• 它根据公司亮点、产品系列、主要亮点、财务表现和策略等参数，介绍了全球口咽念珠菌念珠菌症市场的主要企业。
• 该报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 全球口咽念珠菌念珠菌症市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
• 透过用于分析全球口咽念珠菌念珠菌症市场的各种策略矩阵，将促进相关人员的决策。

目录

第一章 研究目的与前提

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章 市场动态、法规与趋势分析

• 市场动态
  • 促进因素
• 爱滋病毒/爱滋病盛行率增加
• 增加研究经费和计划
• 医疗机构数量增加
• 主要亮点
• 监管场景
• 最近的趋势
• 产品发布/核准
• PEST分析
• 波特的分析
• 合併、收购和合作

第四章全球口咽念珠菌念珠菌症市场 - 冠状病毒 (COVID-19) 大流行的影响

• 新型冠状病毒感染疾病（COVID-19）的流行病学
• 供需面分析
• 经济影响

第五章全球口咽念珠菌症市场，依类型，2019-2031

• 假膜状
• 红斑的
• 超塑性

第六章全球口咽念珠菌症市场，依治疗方法，2019-2031

• 抗真菌剂
• 免疫调节剂

第七章全球口咽念珠菌念珠菌症市场，依途径，2019-2031

• 口服
• 外用
• 其他的

第8章全球口咽念珠菌症市场，依通路，2019-2031

• 医院药房
• 零售药房
• 网路药房

第9章全球口咽念珠菌症市场，依地区，2019-2031

• 北美洲
• 美国
• 加拿大
• 欧洲
• 德国
• 英国
• 西班牙
• 法国
• 义大利
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 中国
• 印度
• 日本
• 澳洲
• 韩国
• ASEAN
• 其他亚太地区
• 拉丁美洲
• 巴西
• 阿根廷
• 墨西哥
• 其他拉丁美洲
• 中东
• 海湾合作委员会国家
• 以色列
• 其他中东地区
• 非洲
• 南非
• 北非
• 中部非洲

第10章竞争格局

• 公司简介
  • Bayer AG
  • Teva Pharmaceuticals
  • Stellar Pharma
  • Pfizer
  • Wockhardt
  • Ranbaxy Laboratories
  • Bristol Laboratories
  • Glenmark Pharmaceutical Ltd
  • GlaxoSmithKline

第11章 章节

• 参考
• 调查方法
• 关于出版商

Global oropharyngeal candidiasis market was valued at US$ 456 Mn in 2023 and is expected to reach US$ 630.4 Mn by 2031, exhibiting at a compound annual growth rate (CAGR) of 4.1% from 2024 to 2031.

Figure 1. Global Oropharyngeal Candidiasis Market Share (%), By Region, 2024

Oropharyngeal candidiasis (OPC) which is also commonly known as oral thrush, is a fungal infection which is caused by the overgrowth of Candida species, predominantly Candida albicans, in the oral and pharyngeal mucous membranes. While Candida is a normal component of the oral microbiota, certain conditions can disrupt the delicate balance of microorganisms, thereby leading to its excessive proliferation. It is frequently observed in individuals with compromised immune systems, such as those with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), undergoing chemotherapy, or taking broad-spectrum antibiotics. It can also occur in patients with diabetes or those who use corticosteroids or wear dentures. The infection is typically characterized by white patches on the tongue, inner cheeks, and roof of the mouth, gums, tonsils, or the back of the throat. These lesions can be slightly raised and may cause discomfort or difficulty in swallowing when severe. It is a condition that has garnered significant attention within medical research and patient care due to its pervasive nature in immunocompromised populations. While Candida is a standard tenant of the oral flora among many individuals without causing harm, various circumstances, such as immunodeficiency, extended antibiotic use, diabetes, and certain medical therapies, can predispose individuals to this opportunistic fungal infection. The hallmark symptoms of this infection consist of creamy white lesions that appear on the mucosal surfaces of the oral cavity and the throat. These lesions are sometimes accompanied by discomfort and can impede proper nutrition and swallowing when they are extensive. The treatment landscape for OPC typically involves antifungal medications, with an emphasis on addressing any underlying conditions that may have led to the fungal overgrowth. Market analysis reveals that the therapeutic area for this condition is significantly influenced by the high prevalence of diabetes and HIV/AIDS globally, with a resultant increase in demand for efficacious antifungal therapies.

Market Dynamics:

Global oropharyngeal candidiasis market is driven by the rising prevalence of HIV/AIDS along with a growing elderly population that is susceptible to fungal infections. Moreover, increasingly aggressive tumor-directed therapies along with frequent use of broad-spectrum antibiotic and corticosteroid therapies spur the risk of oral thrush. However, the market potentially faces restraints from rising generics competition and availability of alternate treatment options.

Key features of the study:

• This report provides in-depth analysis of the global oropharyngeal candidiasis market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global oropharyngeal candidiasis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Bayer AG, Teva Pharmaceuticals, Stellar Pharma, Pfizer, Wockhardt, Ranbaxy Laboratories, Bristol Laboratories, Glenmark Pharmaceuticals Ltd, and GlaxoSmithKline.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global oropharyngeal candidiasis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oropharyngeal candidiasis market.

Detailed Segmentation:

• Global Oropharyngeal Candidiasis Market, By Type
  • Pseudomembranous
  • Erythematous
  • Hyperplastic
• Global Oropharyngeal Candidiasis Market, By Treatment
  • Anti-fungal
  • Immune-modulators
• Global Oropharyngeal Candidiasis Market, By Route of Administration
  • Oral
  • Topical
  • Others
• Global Oropharyngeal Candidiasis Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Oropharyngeal Candidiasis Market, By Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Top Companies in Global Oropharyngeal Candidiasis Market:
  • Bayer AG
  • Teva Pharmaceuticals
  • Stellar Pharma
  • Pfizer
  • Wockhardt
  • Ranbaxy Laboratories
  • Bristol Laboratories
  • Glenmark Pharmaceuticals Ltd
  • GlaxoSmithKline

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Oropharyngeal Candidiasis, By Type
  • Market Oropharyngeal Candidiasis, By Treatment
  • Market Oropharyngeal Candidiasis, By Route of Administration
  • Market Oropharyngeal Candidiasis, By Distribution Channel
  • Market Oropharyngeal Candidiasis, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Driver
• Increasing prevalence of HIV/AIDS
• Rising research funding and projects
• Increasing number of healthcare facilities
• Key Highlights
• Regulatory Scenario
• Recent Trends
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Mergers, Acquisitions, and Collaborations

4. Global Oropharyngeal Candidiasis Market- Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Oropharyngeal Candidiasis Market, By Type, 2019-2031, (US$ Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Pseudomembranous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Erythematous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Hyperplastic
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

6. Global Oropharyngeal Candidiasis Market, By Treatment, 2019-2031, (US$ Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020-2031
  • Segment Trends
• Anti-fungal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Immune-modulators
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

7. Global Oropharyngeal Candidiasis Market, By Route of Administration, 2019-2031, (US$ Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020-2031
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Topical
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

8. Global Oropharyngeal Candidiasis Market, By Distribution Channel, 2019-2031, (US$ Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020-2031
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

9. Global Oropharyngeal Candidiasis Market, By Region, 2019-2031, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2019 -2031
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031 ,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Mn)
• U.S.
• Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Mn)
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Mn)
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Mn)
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Mn)
• GCC Countries
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031, (US$ Mn)
• South Africa
• North Africa
• Central Africa

10. Competitive Landscape

• Company Profile
  • Bayer AG
• Company Highlights
• Type Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Teva Pharmaceuticals
• Company Highlights
• Type Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Stellar Pharma
• Company Highlights
• Type Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Pfizer
• Company Highlights
• Type Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Wockhardt
• Company Highlights
• Type Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Ranbaxy Laboratories
• Company Highlights
• Type Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Bristol Laboratories
• Company Highlights
• Type Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Glenmark Pharmaceutical Ltd
• Company Highlights
• Type Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • GlaxoSmithKline
• Company Highlights
• Type Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Analyst Views

11. Section

• References
• Research Methodology
• About us